Aug 2026· Nano letters (Print)· Vol 26 33, pp.
11067-11078
· 0 citations· 28 references
Medicine
TL;DR
A microfluidic SERS platform integrating plasmonic nanobowl arrays that simultaneously achieve a high enhancement factor and signal reproducibility and provides a promising tool for EV-based precision oncology.
Abstract
Tumor-derived extracellular vesicles (EVs) are promising liquid biopsy biomarkers, yet their clinical translation is hindered by the trade-off between enhancement and reproducibility of SERS-based detection. Here, we present a microfluidic SERS platform integrating plasmonic nanobowl arrays that simultaneously achieve a high enhancement factor and signal reproducibility. Periodic nanobowl architectures generate consistent plasmonic hotspots, breaking the typical compromise between sensitivity and uniformity. The aptamer-modified chip enables quantification of EV markers and achieved a calculated analytical limit of detection of 2.5 × 103 particles mL-1 for purified cell line EVs and 1.2 × 104 particles mL-1 for ultrafiltration-pretreated plasma. In a pancreatic cancer mouse model, the platform tracked tumor progression longitudinally, with SERS signals correlating with bioluminescence imaging (r > 0.83). In a pilot clinical study, multimarker analysis achieved 93.33% diagnostic accuracy and effectively monitored chemotherapy response (AUC = 0.80-0.96). This robust platform provides a promising tool for EV-based precision oncology.
Applying PRISM to CTCs from pancreatic cancer patients, a novel data analysis framework is introduced, including a 'Metastasis Potential Score' (MPS), to translate high-dimensional spectral data into a clinically relevant metric for risk stratification.
Yanrong Wen, Mengxiang Liu, Chun-Hui Liu et al.· ACS Sensors· 0 citations
This review discusses current breakthroughs in aptamer and peptide functionalized microfluidic biosensors for exosome-based cancer diagnostics, focusing on their translation into POC applications, and highlights present challenges, as well as potential future prospects.
P. Priyanka, S. Hemalatha· Microfluidics and Nanofluidi...· 0 citations
The MIRACLE platform is developed, an integrated system combining microfluidic magneto-controllable reversible affinity capture with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) for efficient, multiplexed detection of tumor-derived EV DNA mutations.
Small extracellular vesicles (sEVs, aka, exosomes) are potential biomarkers for breast cancer liquid biopsy, but their nanoscale size and the complexity of plasma make sensitive, reproducible, and scalable measurements challenging. Here we report plasmonic nano-aperture label-free imaging (PANORAMA) assay implemented o...
Abhay Kotnala, S. Mahmud, Omid Mohsen Daraei et al.· Plasmonics· 0 citations
Circulating tumor cells (CTCs), as pivotal targets in liquid biopsy, offer dynamic, multidimensional insights into tumor heterogeneity and metastatic progression. However, their extreme rarity, pronounced heterogeneity, and the complexity of the blood microenvironment severely constrain detection accuracy. Advances in...
Hao Li, Jiao-Jiao Sun, Kun-Guo Liu et al.· Exploration· 0 citations
This review systematically correlates TNBC biomarkers with optimal sensing technologies, emphasizing how biomolecular properties affect sensor selection and performance and emphasizes future integration of biosensors with CTC-derived organoids, microfluidics, AI, and multiplexed detection to enable portable, clinically...
Karim G. Mohammed, M. Abdelgawad, Mohamed S. Attia· Clinica chimica acta; intern...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.